News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
387,042 Results
Type
Article (18713)
Company Profile (109)
Press Release (368214)
Multimedia
Podcasts (66)
Webinars (14)
Section
Business (118547)
Career Advice (518)
Deals (20624)
Drug Delivery (70)
Drug Development (51632)
Employer Resources (54)
FDA (8688)
Job Trends (8332)
News (202428)
Policy (17783)
Tag
Academia (916)
Accelerated approval (9)
Adcomms (9)
Allergies (72)
Alliances (27154)
ALS (81)
Alzheimer's disease (922)
Antibody-drug conjugate (ADC) (119)
Approvals (8833)
Artificial intelligence (253)
Autoimmune disease (27)
Automation (14)
Bankruptcy (192)
Best Places to Work (6472)
BIOSECURE Act (9)
Biosimilars (97)
Biotechnology (45)
Bladder cancer (85)
Brain cancer (33)
Breast cancer (285)
Cancer (2324)
Cardiovascular disease (193)
Career advice (454)
Career pathing (12)
CAR-T (89)
CDC (4)
Cell therapy (286)
Cervical cancer (22)
Clinical research (44662)
Collaboration (813)
Company closure (1)
Compensation (462)
Complete response letters (25)
COVID-19 (1068)
CRISPR (44)
C-suite (337)
Cystic fibrosis (78)
Data (2557)
Denatured (16)
Depression (39)
Diabetes (198)
Diagnostics (2659)
Digital health (14)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (101)
Drug pricing (98)
Drug shortages (13)
Duchenne muscular dystrophy (101)
Earnings (55205)
Editorial (25)
Employer branding (4)
Employer resources (48)
Events (70397)
Executive appointments (686)
FDA (10067)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (628)
Gene editing (89)
Generative AI (12)
Gene therapy (249)
GLP-1 (507)
Government (2030)
Grass and pollen (6)
Guidances (246)
Healthcare (7709)
HIV (27)
Huntington's disease (14)
IgA nephropathy (37)
Immunology and inflammation (103)
Immuno-oncology (5)
Indications (36)
Infectious disease (1160)
Inflammatory bowel disease (103)
Inflation Reduction Act (9)
Influenza (34)
Intellectual property (103)
Interviews (69)
IPO (9483)
IRA (33)
Job creations (2244)
Job search strategy (407)
Kidney cancer (10)
Labor market (22)
Layoffs (232)
Leadership (7)
Legal (4150)
Liver cancer (53)
Longevity (8)
Lung cancer (392)
Lymphoma (171)
Machine learning (14)
Management (18)
Manufacturing (334)
MASH (75)
Medical device (4483)
Medtech (4487)
Mergers & acquisitions (11703)
Metabolic disorders (525)
Multiple sclerosis (76)
NASH (21)
Neurodegenerative disease (91)
Neuropsychiatric disorders (22)
Neuroscience (1443)
NextGen: Class of 2025 (2570)
Non-profit (1397)
Now hiring (15)
Obesity (255)
Opinion (147)
Ovarian cancer (63)
Pain (107)
Pancreatic cancer (91)
Parkinson's disease (137)
Partnered (9)
Patents (225)
Patient recruitment (147)
Peanut (26)
People (34393)
Pharmaceutical (65)
Pharmacy benefit managers (14)
Phase I (12056)
Phase II (19239)
Phase III (16481)
Pipeline (1631)
Policy (122)
Postmarket research (1817)
Preclinical (5099)
Press Release (32)
Prostate cancer (128)
Psychedelics (17)
Radiopharmaceuticals (167)
Rare diseases (354)
Real estate (3084)
Recruiting (18)
Regulatory (13393)
Reports (20)
Research institute (991)
Resumes & cover letters (66)
Rett syndrome (9)
RNA editing (5)
RSV (24)
Schizophrenia (75)
Series A (102)
Series B (68)
Service/supplier (5)
Sickle cell disease (58)
Special edition (11)
Spinal muscular atrophy (93)
Sponsored (14)
Startups (1888)
State (2)
Stomach cancer (12)
Supply chain (55)
Tariffs (60)
The Weekly (48)
Vaccines (344)
Venture capital (34)
Weight loss (146)
Women's health (23)
Worklife (4)
Date
Today (24)
Last 7 days (292)
Last 30 days (1342)
Last 365 days (21513)
2025 (14877)
2024 (21186)
2023 (22676)
2022 (29202)
2021 (30376)
2020 (28602)
2019 (22777)
2018 (17607)
2017 (18796)
2016 (17942)
2015 (21501)
2014 (16972)
2013 (13849)
2012 (14917)
2011 (15715)
2010 (14235)
Location
Africa (369)
Alabama (33)
Alaska (2)
Arizona (99)
Arkansas (6)
Asia (25064)
Australia (3620)
California (5598)
Canada (1761)
China (577)
Colorado (233)
Connecticut (264)
Delaware (180)
Europe (53953)
Florida (779)
Georgia (157)
Hawaii (2)
Idaho (18)
Illinois (474)
India (31)
Indiana (258)
Iowa (7)
Japan (223)
Kansas (74)
Kentucky (22)
Louisiana (5)
Maine (23)
Maryland (670)
Massachusetts (4295)
Michigan (117)
Minnesota (282)
Mississippi (2)
Missouri (79)
Montana (10)
Nebraska (8)
Nevada (52)
New Hampshire (22)
New Jersey (1647)
New Mexico (11)
New York (1462)
North Carolina (735)
North Dakota (4)
Northern California (2505)
Ohio (142)
Oklahoma (9)
Oregon (19)
Pennsylvania (1060)
Puerto Rico (11)
Rhode Island (17)
South America (589)
South Carolina (8)
Southern California (2206)
Tennessee (82)
Texas (840)
United States (20054)
Utah (143)
Virginia (187)
Washington D.C. (53)
Washington State (453)
West Virginia (2)
Wisconsin (64)
387,042 Results for "purdue pharmaceuticals l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.
March 27, 2024
·
7 min read
Bankruptcy
Purdue Files for Bankruptcy Anew to Support $7.4B+ Opioid Settlement
The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the Sackler family too much protection.
March 20, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
May 12, 2025
·
5 min read
Pharm Country
Purdue Pharma L.P. to Provide Funding Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to examine the outcomes associated with the use of Nalmefene Hydrochloride injection, 2mg/2mL (1mg/1mL).
March 28, 2023
·
6 min read
Press Releases
Merit Medical Acquires Biolife Delaware, L.L.C.
May 20, 2025
·
15 min read
Earnings
BioNTech’s Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing
BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said during the company’s Q1 investor call.
May 5, 2025
·
3 min read
·
Tristan Manalac
Press Releases
L7 Informatics Affirms Architecture, Not Data, is the True Moat for AI in Life Sciences
September 12, 2025
·
1 min read
Pharm Country
FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose
Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
April 8, 2024
·
6 min read
Press Releases
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
May 22, 2025
·
8 min read
Press Releases
Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-positive Alzheimer’s Disease
August 22, 2025
·
3 min read
1 of 38,705
Next
